



Notice of Results

September 2, 2021

RNS Number : 5833K

MaxCyte, Inc.

02 September 2021

MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

GAITHERSBURG, MD, September 02, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for *ex vivo* cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details

Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 3199124. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at <https://investors.maxcyte.com/>.

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

MaxCyte Contacts:

MaxCyte Inc.	+1 301-944-1660
Doug Doerfler, Chief Executive Officer	
Amanda Murphy, Chief Financial Officer	

<i>Nominated Adviser and Joint Corporate Broker</i>	+44 (0)20 7886 2500
Panmure Gordon	
Emma Earl / Freddy Crossley	
Corporate Broking	

Rupert Dearden

Joint Corporate Broker

Numis Securities Limited

+44 (0)20 7260 1000

James Black / Duncan

Monteith / Matthew

O'Dowd

Joint Corporate Broker

Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams

UK IR Adviser

Consilium Strategic

+44 (0)203 709 5700

Communications

maxcyte@consilium-

Mary-Jane Elliott

comms.com

Chris Welsh

US IR Adviser

Gilmartin Group

+1 415-937-5400

David Deuchler, CFA

ir@maxcyte.com

US Media Relations

Jamie Lacey-Moreira

+1 410 299-3310

PressComm PR, LLC

jamielacey@presscommpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORLTMJTMTTMBJB